Literature DB >> 8525683

Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.

Z Moldoveanu1, M L Clements, S J Prince, B R Murphy, J Mestecky.   

Abstract

Healthy adult volunteers were immunized by parenteral or oral routes with trivalent inactivated influenza vaccine (A/Chile/1/83 (H1N1), A/Mississippi/1/85 (H3N2), and B/Ann Arbor/1/86), or intranasally with live attenuated, cold-adapted influenza type A/Texas/1/85 (H1N1) reassortant virus. In all volunteers, cells spontaneously secreting IgA, IgG or IgM antibodies specific to influenza virus were detected in peripheral blood on days 6-13 after immunization, and specific IgA, IgG and IgM antibodies to influenza vaccine were measured in sera and external secretions (saliva and nasal lavage). Following systemic immunization, a raise in specific antibodies of all isotypes was observed in sera beginning on day 13. Although small variations in IgA and IgM antibodies in saliva and nasal lavages were detected, antigen-specific IgG significantly increased between days 13 and 27. Intranasal administration of attenuated virus induced IgA and IgG antibodies in serum as well as in secretions. Serum antibodies were not substantially influenced by oral immunization, only a small increase in all isotypes was observed in volunteers' sera 21 days after ingestion of vaccine. However, in secretions, antigen-specific IgA and IgG responses were detected one week after immunization and reached a peak response on day 20. These studies show that different routes of immunization can be effective for the induction of specific antibodies, and support the concept of the common mucosal immune system in humans by demonstrating that the oral or intranasal administration of antigen-induced specific antibodies of IgA isotype in external secretions, preceded by the transient appearance in peripheral blood of specific antibody-producing cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525683     DOI: 10.1016/0264-410x(95)00016-t

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  63 in total

1.  Pilot investigation into the sickness response to influenza vaccination in adults: Effect of depression and anxiety.

Authors:  Jessica A Harper; Charles South; Madhukar H Trivedi; Marisa S Toups
Journal:  Gen Hosp Psychiatry       Date:  2017-07-25       Impact factor: 3.238

2.  Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.

Authors:  Jennifer Humberd Smith; Mark Papania; Darin Knaus; Paula Brooks; Debra L Haas; Raydel Mair; James Barry; S Mark Tompkins; Ralph A Tripp
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

3.  Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.

Authors:  Soumi Gupta; Ramesh Janani; Qian Bin; Paul Luciw; Catherine Greer; Silvia Perri; Harold Legg; John Donnelly; Susan Barnett; Derek O'Hagan; John M Polo; Michael Vajdy
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

5.  Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Authors:  Jiri Mestecky; Peter F Wright; Lucia Lopalco; Herman F Staats; Pamela A Kozlowski; Zina Moldoveanu; Rashada C Alexander; Rose Kulhavy; Claudia Pastori; Leonard Maboko; Gabriele Riedner; Yuwei Zhu; Terri Wrinn; Michael Hoelscher
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-22       Impact factor: 2.205

6.  Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice.

Authors:  N B Saunders; D R Shoemaker; B L Brandt; E E Moran; T Larsen; W D Zollinger
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

7.  Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans.

Authors:  A Rudin; E L Johansson; C Bergquist; J Holmgren
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

8.  A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses.

Authors:  N K Childers; G Tong; S Mitchell; K Kirk; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

9.  Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

Authors:  B Haneberg; R Dalseg; E Wedege; E A Høiby; I L Haugen; F Oftung; S R Andersen; L M Naess; A Aase; T E Michaelsen; J Holst
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

10.  Fusobacterium nucleatum envelope protein FomA is immunogenic and binds to the salivary statherin-derived peptide.

Authors:  Hidetaka Nakagaki; Shinichi Sekine; Yutaka Terao; Masahiro Toe; Muneo Tanaka; Hiro-O Ito; Shigetada Kawabata; Satoshi Shizukuishi; Kohtaro Fujihashi; Kosuke Kataoka
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.